Chemokine antagonism in chronic hepatitis C virus infection

Journal of Clinical Investigation

Volumn 121, Issue 1, 2011, Pages 25-27

  Charles, Edgar D ^a   Dustin, Lynn B ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIGEN; PEGINTERFERON ALPHA; RIBAVIRIN; SITAGLIPTIN;

CYTOKINE PRODUCTION; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL; LIVER DISEASE; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT RESPONSE;

CHEMOKINE CXCL10; CHEMOKINES; DIABETES MELLITUS, TYPE 2; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 78650946377     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45610     Document Type: Note

References (23)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(suppl 1):74-81.
2. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24(suppl 2):3-8.
3. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat. 2007;14(suppl 1):82-88.
4. Casrouge A, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011; 121(1):308-317.
5. Butera D, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106(4):1175-1182. (Pubitemid 41129575)
6. Romero AI, et al. Interferon (IFN)-?-inducible protein 10: association with histological results, viral kinetics, and outcome during treatment with pegylated interferon-?-2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006; 194(7):895-903.
7. Lagging M, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006; 44(6):1617-1625. (Pubitemid 44953667)
8. Diago M, et al. Association of pretreatment serum interferon-? inducible protein levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1-infected patients with chronic hepatitis C. Gut. 2006;55(3):374-379.
9. Qin S, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101(4):746-754.
10. Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun. 2010;34(1):45-54.
11. Narumi S, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol. 1997; 158(11):5536-5544.
12. Harvey CE, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360-369.
13. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163(11):6236-6243.
14. Tan AT, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol. 2010;52(3):330-339.
15. Nishioji K, et al. Increase of chemokine interferon- inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol. 2001;123(2):271-279. (Pubitemid 32174779)
16. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745-1754.
17. Proost P, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 2001;98(13):3554-3561.
18. Andrieu T, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol. 2003;27(1):59-68.
19. Zeremski M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48(5):1440-1450.
20. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut. 2005;54(7):903-906. (Pubitemid 40873898)
21. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592-599.
22. Itou M, et al. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol. 2008;23(2):244-251.
23. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5(1):26-34.